Medical Scientist Training Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Medical Scientist Training Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biology, University of Pennsylvania, Philadelphia, PA, USA.
Cancer Cell. 2021 Aug 9;39(8):1150-1162.e9. doi: 10.1016/j.ccell.2021.05.005. Epub 2021 Jun 10.
The underpinnings of cancer metastasis remain poorly understood, in part due to a lack of tools for probing their emergence at high resolution. Here we present macsGESTALT, an inducible CRISPR-Cas9-based lineage recorder with highly efficient single-cell capture of both transcriptional and phylogenetic information. Applying macsGESTALT to a mouse model of metastatic pancreatic cancer, we recover ∼380,000 CRISPR target sites and reconstruct dissemination of ∼28,000 single cells across multiple metastatic sites. We find that cells occupy a continuum of epithelial-to-mesenchymal transition (EMT) states. Metastatic potential peaks in rare, late-hybrid EMT states, which are aggressively selected from a predominately epithelial ancestral pool. The gene signatures of these late-hybrid EMT states are predictive of reduced survival in both human pancreatic and lung cancer patients, highlighting their relevance to clinical disease progression. Finally, we observe evidence for in vivo propagation of S100 family gene expression across clonally distinct metastatic subpopulations.
癌症转移的基础仍未被充分理解,部分原因是缺乏用于高分辨率探测其发生的工具。在这里,我们提出了 macsGESTALT,这是一种基于诱导型 CRISPR-Cas9 的谱系记录器,能够高效地捕获转录和系统发育信息的单细胞。我们将 macsGESTALT 应用于转移性胰腺癌的小鼠模型,我们回收了约 380,000 个 CRISPR 靶位点,并重建了约 28,000 个单细胞在多个转移部位的扩散。我们发现细胞占据了上皮-间充质转化 (EMT) 状态的连续体。转移潜能在罕见的、晚期杂交 EMT 状态中达到峰值,这些状态从主要的上皮祖细胞池中被积极选择。这些晚期杂交 EMT 状态的基因特征可预测人类胰腺癌和肺癌患者的生存时间缩短,突出了它们与临床疾病进展的相关性。最后,我们观察到证据表明 S100 家族基因表达在克隆不同的转移性亚群中在体内传播。
Dev Cell. 2021-12-6
Cancer Cell. 2021-8-9
Cell Death Differ. 2023-5
bioRxiv. 2025-8-29
NPJ Precis Oncol. 2025-8-27
Signal Transduct Target Ther. 2025-8-1
Nat Rev Clin Oncol. 2025-7-22
Proc Natl Acad Sci U S A. 2019-9-4
Development. 2019-6-27
Cell. 2019-6-6
Nature. 2019-5-13
Semin Cancer Biol. 2020-12